Skip to content

MABVAX THERAPEUTICS HOLDINGS, INC.

CIK 0001109196

← back to feed
Revenue (TTM)
$4.7M
−100.0% YoY Q3 Nov 2018
Net Income (TTM)
−$8.99M
−7.7% YoY Q3 Nov 2018
EPS Diluted (TTM)
—
Q3 Nov 2018
Gross Margin
—
Q3 Nov 2018
Operating Margin
-175.7%
Q3 Nov 2018
Net Margin
-191.2%
Q3 Nov 2018
Free Cash Flow (TTM)
$10.81M
Q3 Nov 2018
Cash
$951.75K
Q3 Nov 2018
Total Debt
$5.36M
Q3 Nov 2018
Shares Outstanding
9.25M sh
Q3 Nov 2018

Revenue & Net Income

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings